This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CytRx: FDA Lifts 2-year Hold On Arimoclomol Tests

LOS ANGELES (AP) ¿ Shares of biopharmaceutical company CytRx Corp. rose in morning trading Wednesday after the Food and Drug Administration lifted a nearly two-year suspension on development of arimoclomol as a treatment for Lou Gehrig's disease.

The news follows approval of a revised clinical trial design for the drug candidate. Shares climbed 12 cents, or 12 percent, to $1.12. The stock has ranged from 24 cents to $1.72 over the past year.

In January 2008, the FDA halted arimoclomol studies, citing the need for additional analysis from previously completed animal studies with arimoclomol. In June 2008, the company said it would have to conduct more animal toxicology studies on the drug candidate.

Lou Gehrig's disease is a progressive condition that affects nerve cells in the brain and spinal cord. Also known as amyotrophic lateral sclerosis or ALS, it currently has no cure or treatment that halts or reverses the condition.

CytRx said it has attracted "significant interest" from several potential partners for arimoclomol, which is in midstage development.

Results from the new midstage study could be available 18 months after the study starts.

Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
CYTR $4.24 0.71%
AAPL $124.95 -0.68%
FB $78.40 1.10%
GOOG $528.68 -0.40%
TSLA $231.35 -0.69%


DOW 17,867.88 -60.32 -0.34%
S&P 500 2,082.59 -6.87 -0.33%
NASDAQ 4,922.9350 -16.3920 -0.33%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs